It was said here that Dr. Patterson’s article was already peer reviewd and will be published soon. I’m also hoping M/M phase 3 is announced soon, that would hopefully mean we have a good chance for approval by the end of the year.
Saltz- I feel exactly the same way. You very well described my thoughts. I wish I had a more optimistic view of the very short term, but I don’t. I am an investor, not a trader. This is my only OTC stock. I have done substantial DD and remain extremely confident in the science of Leronlimab and its potential. I have guarded optimism for current management, though I don’t doubt Nader’s sincerity. We have to wait. We will be pummeled between now and November. But I’m not selling or pulling out. The fundamentals of why I invested in the first place have not changed. Not one bit. There is one side issue to watch and that is the re-submission of the BLA for HIV and a response coming in early September. I’m not overly hopeful for that outcome but it is something that could be a market mover of positive.
News 
Market Data 
Discover 
AI
